Adlai Nortye Group Ltd. ANL
9.06 USD +0.32 (+3.66%)
Regular-session close
9.06 0.00 0.00%
After hours · Nov 19, 4:25 PM ET
8.50 Day range 9.27
0.879 52-week range 17.25
- YTD
- +538.03%
- 1 year
- +520.55%
News
benzinga.com Adlai Nortye Group Reveals Oral Presentation For AN4035 Program Update At the Upcoming 38th EORTC-NCI-AACR Symposium Adlai Nortye Group Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that an oral
globenewswire.com Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class…
globenewswire.com Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial
zacks.com Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
globenewswire.com Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the…
defenseworld.net Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Has Consensus Target Price of $29.50 According to Analysts Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the stock,…
globenewswire.com Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA…
zacks.com Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).
globenewswire.com Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical…
defenseworld.net Adlai Nortye (ANL) to Announce Quarterly Earnings on Thursday Adlai Nortye (NASDAQ: ANL - Get Free Report) is projected to announce its Q2 2026 resultson Thursday, August 6th. Analysts expect Adlai Nortye to announce earnings of ($0.1333) per share and revenue…
globenewswire.com Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and…
globenewswire.com Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on…
globenewswire.com Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the…
zacks.com Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
zacks.com Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
zacks.com Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
globenewswire.com Adlai Nortye Announces $150.0 Million Private Placement Equity Financing SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the…
zacks.com Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
zacks.com Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.
zacks.com Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.
globenewswire.com Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company…
